학술논문
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Document Type
Article
Author
Šimkovič, Martin; Turcsányi, Peter; Špaček, Martin; Mihályová, Jana; Ryznerová, Pavlína; Maco, Mária; Vodárek, Pavel; Écsiová, Dominika; Poul, Hynek; Móciková, Heidi; Zuchnická, Jana; Panovská, Anna; Lekaa, Mohammad; Oršulová, Martina; Prchlíková, Adéla; Stejskal, Lukáš; Mašlejová, Stanislava; Brychtová, Yvona; Bezděková, Lucie; Papajík, Tomáš
Source
Subject
*CHRONIC lymphocytic leukemia
*COVID-19
*BRUTON tyrosine kinase
*COVID-19 treatment
*PHOSPHATIDYLINOSITOL 3-kinases
*
*
*
*
Language
ISSN
0939-5555
Abstract
Patients with chronic lymphocytic leukemia (CLL) have a high risk of poor outcomes related to coronavirus disease 2019 (COVID-19). This multicenter cohort study evaluated the impact of COVID-19 infection on the population of CLL patients in the Czech Republic. Between March 2020 and May 2021, 341 patients (237 males) with CLL and COVID-19 disease were identified. The median age was 69 years (range 38–91). Out of the 214 (63%) patients with the history of therapy for CLL, 97 (45%) were receiving CLL-directed treatment at diagnosis of COVID-19: 29% Bruton tyrosine kinase inhibitor (BTKi), 16% chemoimmunotherapy (CIT), 11% Bcl-2 inhibitor, and 4% phosphoinositide 3-kinase inhibitor. Regarding the severity of COVID-19, 60% pts required admission to the hospital, 21% pts were admitted to the intensive care unit (ICU), and 12% received invasive mechanical ventilation. The overall case fatality rate was 28%. Major comorbidities, age over 72, male gender, CLL treatment in history, CLL-directed treatment at COVID-19 diagnosis were associated with increased risk of death. Of note, concurrent therapy with BTKi compared to CIT was not associated with better outcome of COVID-19. [ABSTRACT FROM AUTHOR]